Radically Resected Pituitary Adenomas: Prognostic Role of Ki 67 Labeling Index in a Monocentric Retrospective Series and Literature Review
Overview
Authors
Affiliations
Ki-67 Labeling Index is an immunocytochemical marker of cell proliferation. The correlation of Ki-67 expression with pituitary adenomas recurrence has been investigated and is highly debated. Aim of this study was to evaluate whether Ki-67 correlates with recurrence even in patients with an apparently completely removed pituitary adenoma. We retrospectively reviewed the database of the Hypothalamic-Pituitary Disease Unit at the Catholic University of Rome, collected between 2003 and 2011. Inclusion criteria were: patients who underwent surgery at the Department of Neurosurgery with an apparently complete removal of a pituitary adenoma; Ki-67 histological evaluation by the same operator and values of <3%. All patients underwent endocrine evaluation of the hypothalamic-pituitary function, ophthalmologic and neuro-radiological examinations, during the preoperative period and follow-up. Out of 490 patients recorded on the database of the Hypothalamic-Pituitary Disease Unit at the Catholic University of Rome, 191 cases met the inclusion criteria. Recurrence was observed in 49 cases (25.7% of the patients who had undergone radical excision). Optional cut-off value was identified at Ki-67 values of 1.50%. This was associated with worse disease-free survival time, even after correction for age at treatment, gender, positivity to p53, functional classification and Knosp grading. Ki-67 labeling index may be useful in postoperative management, even in patients who underwent radical PA removal. We suggest a Ki-67 cut-off value of 1.5% to plan an adequate clinical follow-up.
Chiloiro S, Mattogno P, Angelini F, Giampietro A, Vicari A, Konini G Pituitary. 2025; 28(2):37.
PMID: 40064752 PMC: 11893686. DOI: 10.1007/s11102-025-01505-4.
Chiloiro S, Giampietro A, Giambo P, Costanza F, Mattogno P, Lauretti L Pituitary. 2024; 28(1):7.
PMID: 39724447 DOI: 10.1007/s11102-024-01479-9.
[Quantification of Ki-67 in PitNET (pituitary neuroendocrine tumors)/adenomas].
Klein J, Saeger K, Saeger W Pathologie (Heidelb). 2024; 45(5):339-343.
PMID: 38992316 PMC: 11343892. DOI: 10.1007/s00292-024-01319-4.
Ishida A, Inoshita N, Tanabe N, Takano K, Tanaka-Mizuno S, Kato M Front Endocrinol (Lausanne). 2024; 15:1400671.
PMID: 38863935 PMC: 11165050. DOI: 10.3389/fendo.2024.1400671.
High Ki67 Gene Expression Is Associated With Aggressive Phenotype in Hepatocellular Carcinoma.
Ramos-Santillan V, Oshi M, Nelson E, Endo I, Takabe K World J Oncol. 2024; 15(2):257-267.
PMID: 38545476 PMC: 10965267. DOI: 10.14740/wjon1751.